CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple SclerosisMultiple sclerosis relapseMultiple Sclerosis, Primary Progressive+ [5]

Inactive Indication

Follicular LymphomaHashimoto's EncephalitisLupus Nephritis+ [2]

Originator Organization

Genentech, Inc.

Biogen Idec Ltd.

Active Organization

Hoffmann-La Roche Ltd.Hoffmann-La Roche, Inc.Roche Pharma (Schweiz) AG

+ [5]

Inactive Organization

Roche Pharma AG

License Organization

Genentech, Inc.

Biogen, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (28 Mar 2017),

Multiple sclerosis relapseMultiple Sclerosis, Primary Progressive

RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (South Korea)

Structure/Sequence

Sequence Code 31212L

Source: *****

Sequence Code 42721H

Source: *****

109

Clinical Trials associated with Ocrelizumab

NCT06677710

/ SuspendedPhase 1

A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis

This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.

Start Date30 Jun 2026

Sponsor / Collaborator

Indapta Therapeutics, Inc.

NCT07282574

/ Not yet recruitingPhase 2

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Start Date30 Jan 2026

Sponsor / Collaborator

Roche Holding AG

NCT07207148

/ Not yet recruitingNot ApplicableIIT

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.
For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.
For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.

Start Date15 Dec 2025

Sponsor / Collaborator

Northwestern University

[+1]

100 Clinical Results associated with Ocrelizumab

100 Translational Medicine associated with Ocrelizumab

100 Patents (Medical) associated with Ocrelizumab

1,154

Literatures (Medical) associated with Ocrelizumab

01 Dec 2025·Multiple Sclerosis and Related Disorders

Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study

Article

Author: Pinel, Sylvine ; Bihan, Kevin ; Brochard, Vincent ; Bensa, Caroline ; Le Vavasseur, Benjamin ; Papeix, Caroline ; Deschamps, Romain ; Chaugne, Emeline ; Boudot de la Motte, Marine ; Bourneau Martin, Delphine

BACKGROUND:

Ocrelizumab, an anti-CD20 monoclonal antibody, has proven effective in reducing relapses and disease progression in multiple sclerosis. While neutropenia is a known adverse effect of anti-CD20 therapies, data on the clinical severity, recurrence risk, and management of ocrelizumab-induced neutropenia (OIN) remain limited.

OBJECTIVES:

Describe clinical severity, recurrence risk and management of OIN.

METHODS:

We performed a retrospective observational study based on OIN reports from the French Pharmacovigilance Database. A questionnaire was sent to clinicians who had reported cases. Patients with moderate or severe neutropenia (< 1.0 G/L) were included.

RESULTS:

Thirty-four cases of OIN were analysed. Neutropenia was mostly late-onset (>4 weeks post-cycle, 94.1 %) and occurred mainly after the first (32.4 %), second or third cycle (26.5 %). Most patients (55.9 %) were asymptomatic, 32.4 % developed infections and 11.8 % presented agranulocytosis symptoms. Ocrelizumab was reintroduced in 15 patients, with recurrence in 4 cases (26.6 %). Two cases of recurrent neutropenia were reported after switching to ofatumumab.

CONCLUSION:

OIN is an intermittent adverse event, often discovered incidentally and generally not severe. Most cases are likely to go undetected as asymptomatic. With a recurrence rate of 25 %, rechallenging with ocrelizumab should be considered based on MS condition of the patient and available alternative treatment.

01 Dec 2025·Multiple Sclerosis and Related Disorders

Progression independent of relapse activity (PIRA) in the Era of high-efficacy treatments

Article

Author: Liguori, Nora Fernandez ; Miguez, Jimena ; Alonso, Ricardo ; Piedrabuena, Raul ; Liwacki, Susana ; Mainella, Carolina ; Rojas, Juan Ignacio ; Zanga, Gisela ; Cabrera, Lorena Mariela ; Silva, Berenice ; Cohen, Leila ; Patrucco, Liliana ; Eizaguirre, Maria Barbara ; Lazaro, Luciana ; Casas, Magdalena ; Leguizamon, Felisa ; Tizio, Santiago ; Pita, Cecilia ; Carnero Contentti, Edgar ; Tkachuk, Veronica

BACKGROUND:

Progression independent of relapse activity (PIRA) is a key marker of chronic neurodegeneration in multiple sclerosis (MS), reflecting sustained disability progression unrelated to inflammatory relapses. While high-efficacy therapies (HETs) have significantly reduced relapse-associated worsening (RAW), the contribution of PIRA to disability progression has increased in recent diagnostic periods.

OBJECTIVES:

This study aimed to evaluate the prevalence and predictors of PIRA in Argentine patients with relapsing-remitting MS (RRMS) receiving HETs and to explore the impact of early treatment initiation on disease progression.

METHODS:

A post hoc analysis of the Argentine MS registry (RelevarEM) was conducted, including RRMS patients treated with natalizumab, alemtuzumab, cladribine (Cladribine), rituximab, or ocrelizumab. Patients required ≥1 relapse in the preceding 12 months, biannual EDSS assessments, and annual MRI scans. PIRA was defined as EDSS progression (≥1.0 or ≥0.5 points, depending on baseline score) confirmed 24 weeks apart, outside the relapse period. Logistic regression identified predictors of PIRA.

RESULTS:

Among 287 patients (68.2 % female, mean age 37.33±11.10 years), 22 (7.7 %) developed PIRA. PIRA patients were older (42.58±13.46 vs. 36.85±10.79 years, p = 0.015) and had longer disease duration (6.87±6.18 vs. 4.41±4.96 years, p = 0.023). Treatment-naïve patients showed lower PIRA risk (OR=0.10, p = 0.0049), while absence of prior relapses increased risk (OR=8.17, p = 0.0087).

CONCLUSIONS:

PIRA prevalence was lower in this cohort compared to prior studies, reflecting the effectiveness of HETs in RRMS. Early initiation of HETs is critical to mitigating PIRA and long-term disability. These findings underscore the need for timely diagnosis and treatment to alter MS progression.

01 Dec 2025·Multiple Sclerosis and Related Disorders

Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study

Article

Author: Kremer, Laurent ; Didierjean, Judicaelle ; Lanotte, Livia ; Collongues, Nicolas ; Courtois, Sylvie ; Carré, Germain ; De Seze, Jerome ; Bigaut, Kévin

BACKGROUND:

The evolution of the therapeutic arsenal, diagnostic criteria and recommendations concerning treatment in multiple sclerosis (MS) have led to a change in the practices of neurologists in this disease. Our study focuses on the evolution of the prescriptions of a disease-modifying treatment (DMT) in relapsing-remitting (RR) MS by neurologists with a private practice, hospital, or MS center activity, between 2007 (introduction of natalizumab) and 2022 (current practice).

METHODS:

We conducted a multicenter, descriptive retrospective study, focusing on the prescription of DMTs for patients with RRMS in the Alsace region in France. The study encompassed prescriptions initiated between January 2007 and July 2022, for patients who had undergone a brain MRI within 6 months of disease onset. The DMTs considered as high efficacy included fingolimod, cladribine, rituximab, ocrelizumab, ofatumumab, and natalizumab.

MAIN RESULTS:

In our study, focused on the initial prescription of DMTs for RRMS involving a cohort of 1155 patients, we observed a significant time reduction before the first DMT was prescribed, from approximately 1 year during the 2007-2010 period to less than 4 months in the more recent 2018-2022 timeframe. The proportion of high-efficacy treatments (HET) increased notably during the later period interval compared to the earlier ones and there was a discernible change in the profiles of patients initiating HET. These disparities in treatment and patient profiles were particularly pronounced among neurologists practicing within specialized centers or hospitals, in contrast to those engaged in private practices.

CONCLUSIONS:

These results witness a change in decision-making regarding the prescription of the initial DMT in RR-MS by neurologists between 2007 and 2022.

273

News (Medical) associated with Ocrelizumab

17 Dec 2025

·www.globenewswire.com

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo The safety profile of tolebrutinib was consistent with previous studies December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpoint in delaying time to 6-month composite confirmed disability progression (cCDP) in participants with primary progressive multiple sclerosis (PPMS), which represents 10% of the overall multiple sclerosis patient population. Based on these results, Sanofi will not pursue regulatory registration for PPMS. "We are disappointed by today’s results; however, we do believe that these results will improve our understanding of the underlying disease biology of multiple sclerosis,” said Houman Ashrafian, Executive Vice President, Head of Research & Development at Sanofi. “We extend our deepest appreciation to the study participants, their families, and healthcare professionals who support our scientific and innovative vision. Our commitment to the multiple sclerosis community remains unchanged, as do our efforts to pursue novel advancements that address existing unmet needs and we remain confident in the value tolebrutinib can bring to those living with non-relapsing secondary progressive multiple sclerosis.” Preliminary analysis showed the safety profile was consistent with previous tolebrutinib studies. As previously reported, drug-induced liver injury (DILI) is an identified risk of tolebrutinib. Strict adherence to liver monitoring requirements, and prompt management of liver enzyme elevations, are important to mitigate DILI risk. Full safety and efficacy results will be presented at a forthcoming medical meeting. Tolebrutinib was provisionally approved in the United Arab Emirates in July 2025 for the treatment of non-relapsing secondary progressive multiple sclerosis and to slow disability accumulation independent of relapse activity in adults. It is currently under regulatory review in the EU and other jurisdictions worldwide. Tolebrutinib was previously granted breakthrough therapy designation by the FDA in December 2024. Sanofi will conduct an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026. The outcome of this test will have no impact to the business net income / business EPS and there is no change to the financial guidance for 2025. MS is a progressive neurologic disorder characterized by accumulation of disability with shifts in the underlying biology and dominant drivers of disability over time impacting clinical presentation and treatment response. The clinical presentation of PPMS is characterized by a slow, insidious neurologic decline, often with a predominance of spinal cord involvement, and symptoms gradually worsen over time without periods of improvement. Secondary progressive multiple sclerosis typically refers to people with a previous diagnosis of relapsing MS who have stopped experiencing relapses but continue to experience disability accumulation, in the absence of relapses. Addressing disability accumulation remains a significant unmet need in MS, as treatment options are limited. PERSEUS (clinical study identifier: NCT04458051) is a global, double-blind, randomized phase 3 clinical study which evaluated the efficacy and safety of tolebrutinib compared to placebo in participants with PPMS. Participants were randomized (2:1) to receive either an oral daily dose of tolebrutinib or matching placebo for up to approximately 60 months. The inclusion criteria for the study included participants aged 18–55 years old, a diagnosis of PPMS as per the 2017 revised McDonald criteria, an EDSS score ≥2.0 and ≤6.5 at screening, positive cerebrospinal fluid findings (OCBs and/or elevated IgG index) and either no access, intolerance, or perceived lack of efficacy to ocrelizumab. The primary endpoint was six-month composite confirmed disability progression (cCDP), defined as increase over at least six months of ≥1.0 point from the baseline expanded disability status scale (EDSS) score when the baseline score is ≤5.5, or ≥0.5 points when the baseline EDSS score is >5.5, or ≥20% from the baseline T25-FW, or ≥20% from the baseline 9-HPT. Secondary endpoints included six-month confirmed disability progression, three-month cCDP, number of new/enlarging T2 lesions as detected by MRI, time to confirmed disability improvement, change in brain volume loss, change in cognitive function, quality of life, pharmacokinetics, as well as the safety and tolerability of tolebrutinib. Tolebrutinib is an investigational, oral, brain-penetrant Bruton’s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS. This mechanism addresses the underlying pathology of progressive MS by targeting the inflammatory processes that contribute to neurodegeneration and disability accumulation. Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape. Standing at the intersection of neurology and immunoscience, Sanofi is focused on improving the lives of those living with serious neuro-inflammatory and neuro-degenerative conditions including MS, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease, Parkinson’s disease, and age-related macular degeneration. The neurology pipeline currently has several projects in phase 3 studies across various diseases. Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultBreakthrough TherapyDrug Approval

15 Dec 2025

·firstwordpharma.com

Double dose of bad news for Sanofi's BTK inhibitor tolebrutinib

Sanofi announced Monday that tolebrutinib fell short on the main efficacy goal of delaying disability progression in a pivotal study for primary progressive multiple sclerosis (PPMS), prompting the company to abandon regulatory filing plans in this indication.At the same time, the drugmaker also said the FDA target action date for the brain-penetrant BTK inhibitor in non-relapsing secondary progressive multiple sclerosis (nrSPMS) — earlier pushed back from Sep. 28 to Dec. 28 — is likely to be further delayed. The double-dose of bad news sent Sanofi's shares down nearly 5%.The Phase III PERSEUS study enrolled 767 patients aged 18–55 with confirmed PPMS diagnosis and limited access or response to Roche’s Ocrevus (ocrelizumab). Participants were randomised to receive either tolebrutinib or placebo for approximately 60 months.Top-line results showed no significant benefit of tolebrutinib over placebo on the primary endpoint of composite confirmed disability progression (cCDP), which assessed changes in expanded disability status scale (EDSS) score from baseline over at least six months.Sanofi said a preliminary safety analysis of PERSEUS showed consistency with previous tolebrutinib studies, though drug-induced liver injury — which previously led to a partial clinical hold by the FDA — remains an established risk with the BTK inhibitor class. The pharma noted the detailed data will be presented at an upcoming medical meeting, while the financial impact of the failure will be disclosed alongside its next quarterly results."We are disappointed…however, we do believe that these results will improve our understanding of the underlying disease biology," said Houman Ashrafian, R&D head at Sanofi, adding that the company "remain[s] confident in the value tolebrutinib can bring to those living with [nrSPMS]."Sanofi explained that the delay to the FDA's review in nrSPMS comes after the company submitted an expanded access protocol in response to a request from the agency. The drugmaker added that further guidance from the FDA is expected by the end of the first quarter of 2026.Besides the US, the drug also remains under scrutiny in the EU to treat nrSPMS and secured provisional approval in the United Arab Emirates earlier this year for the same indication.Meanwhile, last month, Roche touted favourable results from a pair of pivotal trials evaluating its rival BTK inhibitor fenebrutinib in both relapsing MS and PPMS, further intensifying the competition in the disease area.

Clinical ResultPhase 3

15 Dec 2025

·www.biospace.com

Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application

iStock, PaperFox Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another. Sanofi reported a double whammy of bad news for multiple sclerosis drug tolebrutinib on Monday. The investigational therapy failed to slow disability progression in a Phase III trial, while on the regulatory side, it faces yet another delay for an approval application in progressive disease. Starting with the trial , the BTK inhibitor was being studied in patients with primary progressive multiple sclerosis (PPMS) in the Phase III PERSEUS trial. This indication applies to about 10% of patients with MS. The study failed to meet its primary endpoint, a measure of disability progression when compared with placebo. Sanofi did not provide specific numbers but said it would not pursue regulatory applications in PPMS. Leerink Partners, in a series of notes leading up to the readout, had been anticipating the study to be a success. Specifically, the firm believed Sanofi’s offering would beat Roche’s approved MS drug Ocrevus on delaying disease progression compared to placebo at week 24. The French pharma was also mum on the potential for liver injury with tolebrutinib in the Monday press release. While Sanofi acknowledged the risk of drug-induced liver injury associated with tolebrutinib, it did not provide detailed safety results from the PERSEUS trial, simply noting that results were consistent with previous studies. Leerink had been keenly awaiting these stats to weigh the potential for success of tolebrutinib’s existing FDA application for secondary progressive multiple sclerosis (SPMS). On the regulatory front, the FDA has once again delayed a decision on tolebrutinib’s application for non-relapsing secondary progressive multiple sclerosis (nrSPMS). In September, the agency pushed back the decision timeline to December 28. Sanofi now says the decision has been delayed again and no firm date has been provided. The FDA requested additional information on an expanded access protocol in nrSPMS. The FDA will provide an updated decision date by the end of the first quarter of 2026, Sanofi said. Leerink called today’s updates “disappointing” in a brief note on Monday morning. The firm had been projecting sales of about $1.1 billion for the drug. Rival Roche also has a BTK inhibitor in development called fenebrutinib, which Leerink said has already demonstrated similar efficacy to Ocrevus in PPMS. Sanofi’s tolebrutinib has had a tough path through the clinic, with several failures as well as cases of liver injury that spurred clinical holds from the FDA. In September 2024, Sanofi finally reported Phase III success in the HERCULES trial, with the drug delaying disease progression by 31% in patients with nrSPMS. These results teed up the regulatory filing that is now once again being pushed back. The HERCULES trial also showed an increase in adverse events, including a rate of liver enzyme elevations in 4.1% of patients who took the study drug. Most resolved without issue, but a patient who underwent a liver transplant after treatment died. Sanofi implemented changes to the study protocol to boost liver monitoring. Designed to be administered orally, tolebrutinib is a small molecule inhibitor of the BTK protein, which under healthy circumstances is important for the development and activity of antibody-producing B cells. Tolebrutinib’s mechanism of action allows it to suppress B cells and the disease-driving microglia. Sanofi came to own tolebrutinib in the $3.7 billion acquisition of Principia Biopharma in August 2020.

Phase 3AcquisitionClinical Result

100 Deals associated with Ocrelizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D05218	Ocrelizumab	L04AA36	DB11988

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	Australia	Roche Holding AG	13 Jul 2017
Multiple sclerosis relapse	United States	Genentech, Inc.	28 Mar 2017
Multiple Sclerosis, Primary Progressive	United States	Genentech, Inc.	28 Mar 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Chronic Progressive	Phase 3	United States	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Bosnia and Herzegovina	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Brazil	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Canada	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Colombia	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Costa Rica	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Czechia	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Denmark	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	Egypt	Hoffmann-La Roche, Inc.	28 May 2018
Multiple Sclerosis, Chronic Progressive	Phase 3	France	Hoffmann-La Roche, Inc.	28 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04998812 (MINORE, CTgov)	Phase 4	Clinically isolated syndrome \| Multiple Sclerosis	70	ocrelizumab	zulqcjcklm = ojnsrdlhxx sjxwyfcrjf (xmpmjbdzpl, yxctsauoox - fijycgkhuu) View more	-	22 May 2025
NCT05232825 (OCARINA II, Pubmed \| Neurology)	Phase 3	Multiple Sclerosis	-	Ocrelizumab IV 600 mg	eagrykfwmq(uwepqhfbyi) = All IRs were mild/moderate; intensity and duration decreased with subsequent injections talgbvizvt (hsenqvetsd )	Positive	13 May 2025
				Ocrelizumab SC 920 mg
NCT04925557 (CTgov)	Phase 2/3	Multiple Sclerosis, Secondary Progressive	8	Ocrevus (Ocrevus)	buprvougln(oecgtemuvh) = tyrrdtzpar nzcrjqpsxq (nlgossvgcc, bvrrkafojv - aebqbdclbj) View more	-	13 May 2025
				Mayzent (Mayzent)	buprvougln(oecgtemuvh) = clbdgrljie nzcrjqpsxq (nlgossvgcc, fgdyoskies - zkymmszbnr) View more
NCT04998851 (SOPRANINO, CTgov)	Phase 4	Clinically isolated syndrome \| Multiple Sclerosis \| Carcinoma in situ of uterine cervix	26	MMR vaccine+ocrelizumab (Infants)	upmthvxwym = qyrbvtmrgx uywqthvcdl (khpznarjiu, anfyyehzkb - mpjtgxbtyc) View more	-	16 Apr 2025
				ocrelizumab (Mothers)	exstjwosje(pbyjwpyijt) = gzvovmjlbt zcfxuyatsr (yiqthowvxn, menvivxtfo - mslaiptclp) View more
AAN2025	Phase 3	Multiple Sclerosis Third line JCV antibody \| hypogammaglobulinemia	300	Ocrelizumab	bzksuidosx(llkfcvizie) = reqsfahcaw dtrlynzdby (oogsnbvqwx ) View more	-	07 Apr 2025
P7-1.005 (AAN2025)	Not Applicable	Multiple sclerosis relapse CD20	881	Ocrelizumab	uugrqiemod(nrgloarqan) = The most common side effects leading to discontinuation were infusions reactions (17/47, 36.1%), infections (9/47, 19.1%), and allergy (9/47, 19.1%) gimfkdpzhu (ljmzurkpzk )	Positive	07 Apr 2025
				Rituximab
NCT05232825 (OCARINA II, AAN2025)	Phase 3	Multiple Sclerosis, Primary Progressive \| Multiple sclerosis relapse	-	Ocrelizumab IV 600 mg	urlpvrxzrg(eqmbwtkzxg) = kqdrsigjjv rwlwwpleec (rvcfekqjtj ) View more	Positive	07 Apr 2025
				Ocrelizumab SC 920 mg	urlpvrxzrg(eqmbwtkzxg) = jmafnfnupn rwlwwpleec (rvcfekqjtj ) View more
NCT04377555 (CHIMES, AAN2025)	Phase 4	Multiple Sclerosis neurofilament light chain (NfL) \| glial fibrillary acidic protein (GFAP)	-	Ocrelizumab	kmebrljyua(cajpjayyna) = =0.1 lckqlthuel (zvpzzujkfp ) View more	Positive	07 Apr 2025
				Placebo
P10-1.004 (AAN2025)	Not Applicable	Multiple Sclerosis anti-CD20-antibodies	192	Anti-CD20-antibodies	najactmbos(zxtiiutxlg) = vgsthjczsl vwceztemgj (sujlniavmw )	Positive	07 Apr 2025
NCT01412333 \| NCT01247324 (OPERA I/II, Pubmed \| Mult Scler Relat Disord)	Phase 3	Multiple sclerosis relapse	1,656	Ocrelizumab	rsnsmxwrhm(xsyaebnujc) = qjwyoblayy xjxdnnbmxf (hojsosvydu ) View more	Positive	01 Mar 2025
				Interferon beta-1a	rsnsmxwrhm(xsyaebnujc) = yygrdyqixz xjxdnnbmxf (hojsosvydu ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis